Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Puma Biotechnology Inc
PBYI | US
6.98
USD-0.14
-1.97%
PBYI | US
Loading StockChartView...
About Puma Biotechnology Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
6.98
Open
7.05
High
7.05
Low
6.88
Puma Biotechnology Inc. a biopharmaceutical company focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 (neratinib oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; and for HER2 mutation-positive solid tumors. Its products also includes PB272 (neratinib intravenous) and PB357. It has a license agreement with Pfizer Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd. CANbridge BIOMED Limited Pint Pharma International SA Knight Therapeutics Inc. Pierre Fabre Medicament SAS and Bixink Therapeutics Co. Ltd. The company was founded in 2010 and is headquartered in Los Angeles California.
View LessPBYI | US
Risk
32.7
Sharpe
1.54
Luna's Score
37/100
Recommendation
Sell
Luna says (PBYI | US)
What's Working
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
24.2%1 month
32.7%3 months
37.6%6 months
56.0%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
15.16
Fwd. PE
3.89
Price to book
2.91
Debt to equity
2.03
Debt to assets
0.48
Ent. to EBITDA
4.08
Ent. to rev.
0.65
PEG
0.03
Other Fundamentals
EBITDA
31.10M
MarketCap
342.35M
MarketCap(USD)
342.35M
Div. yield
-
Op. margin
-4.63
Erngs. growth
-78.10
Rev. growth
-13.70
Ret. on equity
22.10
Short ratio
11.44
Short perc.
8.20
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.85
Range1M
1.27
Range3M
2.05
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.06
Price X volume
2.14M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 4.08 | 0.53 | Expensive |
| Ent. to Revenue | 0.65 | 3,967.00 | Cheaper |
| PE Ratio | 15.16 | 41.03 | Cheaper |
| Price to Book | 2.91 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 37.62 | 72.80 | Lower Risk |
| Debt to Equity | 2.03 | -1.23 | Expensive |
| Debt to Assets | 0.48 | 0.25 | Expensive |
| Market Cap | 342.35M | 3.66B | Emerging |
